As third-generation cancer therapeutic agents, immune checkpoint inhibitors that are involved in T-cell regulation such as PD-L1 antibodies have been successfully validated in preclinical models and are currently used in clinical settings against different types of cancers. Here, CD274 is linked to cancer.